Birdshot chorioretinopathy

Current Opinion in Ophthalmology

Volumn 25, Issue 6, 2014, Pages 488-494

  Emily, H ^a,b   Victor, M ^c,d   Taylor, Simon R J ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c Institut Catala de Retina   (Spain)

^d Castellon Provincial Hospital   (Spain)

Author keywords

Birdshot chorioretinopathy; HLA A29; Interleukin antagonists; Monoclonal antibodies; Retinal vasculitis; Th17 cells

Indexed keywords

BIOLOGICAL PRODUCT; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17;

BIRDSHOT CHORIORETINOPATHY; CHORIORETINOPATHY; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; HUMAN; IMMUNOGENETICS; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PERIMETRY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH17 CELL; VISUAL ACUITY; CHORIORETINITIS; IMMUNOLOGY; PHYSIOLOGY; VISUAL FIELD;

CHORIORETINITIS; FLUORESCEIN ANGIOGRAPHY; HUMANS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VISUAL FIELDS;

EID: 84921824867     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0000000000000101     Document Type: Review

References (52)

1. Levinson RD, Brezin A, Rothova A, et al. Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol 2006; 141:185-187.
2. Shah KH, Levinson RD, Yu F, et al. Birdshot chorioretinopathy. Surv Ophthal-mol 2005; 50:519-541.
3. Pagnoux C, Mahr A, Aouba A, et al. Extraocular manifestations of birdshot chorioretinopathy in 118 French patients. Presse Med 2010; 39:e97-e102.
4. Rothova A, Berendschot TT, Probst K, et al. Birdshot chorioretinopathy: longterm manifestations and visual prognosis. Ophthalmology 2004; 111:954-959.
5. Zamecki KJ, Jabs DA. HLA typing in uveitis: use and misuse. Am J Ophthalmol 2010; 149:189-193.
6. Brezin AP, Monnet D, Cohen JH, Levinson RD. HLA-A29 and birdshot chorioretinopathy. Ocul Immunol Inflamm 2011; 19:397-400.
7. Holak HM, Szymaniec S, Holak SA. The pathogenesis of birdshot chorior-etinopathy. Surv Ophthalmol 2006; 51:446-447.
8. Kuiper JJ, Mutis T, de Jager W, et al. Intraocular interleukin-17 and pro-inflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy. Am J Ophthalmol 2011; 152:177-182.
9. Yang P, Foster CS. Interleukin 21, interleukin 23, and transforming growth factor beta1 in HLA-A29-associated birdshot retinochoroidopathy. Am J Ophthalmol 2013; 156:400-406.
10. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013; 120:777-787.
11. de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011; 30:452-470.
12. Tomkins-Netzer O, Taylor SR, Lightman S. Long-term clinical and anatomic outcome of birdshot chorioretinopathy. JAMA Ophthalmol 2014; 132:57-62.
13. Levinson RD, Monnet D, Yu F, et al. Longitudinal cohort study of patients with birdshot chorioretinopathy. V. Quality of life at baseline. Am J Ophthalmol 2009; 147:346-350.
14. Papadia M, Herbort CP. Reappraisal of birdshot retinochoroiditis (BRC): a global approach. Graefes Arch Clin Exp Ophthalmol 2013; 251:861-869.
15. Giuliari G, Hinkle DM, Foster CS. The spectrum of fundus autofluorescence findings in birdshot chorioretinopathy. J Ophthalmol 2009; 2009:567693.
16. Monnet D, Levinson RD, Holland GN, et al. Longitudinal cohort study of patients with birdshot chorioretinopathy. III. Macular imaging at baseline. Am J Ophthalmol Dec 2007; 144:818-828.
17. Taylor SR, Lightman SL, Sugar EA, et al.The impact of macular edema on visual function in intermediate, posterior, and panuveitis. Ocul Immunol Inflamm 201 2; 20:1 71-181.
18. Papadia M, Jeannin B, Herbort CP. OCT findings in birdshot chorioretinitis: a glimpse into retinal disease evolution. Ophthalmic Surg Lasers Imaging 2012; 43 (Suppl 6):S25-S31.
19. Birch DG, Williams PD, Callanan D, et al. Macular atrophy in birdshot retinochoroidopathy: an optical coherence tomography and multifocal elec-troretinography analysis. Retina 2010; 30:930-937.
20. Kempen JH, Sugar EA, Jaffe GJ, et al. Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmol ogy 2013; 120:1852-1859.
21. Keane PA, Allie M, Turner SJ, et al. Characterization of birdshot chorioretinopathy using extramacular enhanced depth optical coherence tomography. JAMA Ophthalmol 2013; 131:341-350.
22. Holder GE, Robson AG, Pavesio C, Graham EM. Electrophysiological characterisation and monitoring in the management of birdshot chorioretinopathy. Br J Ophthalmol 2005; 89:709-718.
23. Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology 2005; 112:1066-1071.
24. Thorne JE, Jabs DA, Kedhar SR, et al. Loss of visual field among patients with birdshot chorioretinopathy. Am J Ophthalmol 2008; 145:23-28.
25. Giuliari GP, Pujari S, Shaikh M, et al. Microperimetry findings in patients with birdshot chorioretinopathy. Can J Ophthalmol 2010; 45:399-403.
26. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008; 4:525-533.
27. Becker MD, Wertheim MS, Smith JR, Rosenbaum JT. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm 2005; 13:289-293.
28. Joshi L, Talat L, Yaganti S, et al. Outcomes of changing immunosuppressive therapy after treatment failure in patients with noninfectious uveitis. Ophthal mology 2014; 121:1119-1124.
29. Taylor SR, Singh J, Menezo V, et al. Behcet disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol 2011; 152:1059-1066.
30. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003; 110:1449-1453.
31. Artornsombudh P, Gevorgyan O, Payal A, et al. Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology 2013; 120:588-592.
32. Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012; 119:1575-1581.
33. Sobrin L, Huang JJ, Christen W, et al. Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol 2008; 126:186-191.
34. Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 2009; 48:347-354.
35. Muselier A, Bielefeld P, Bidot S, et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 2011; 19:382-383.
36. Raveney BJ, Copland DA, Nicholson LB, Dick AD. Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease. Arch Ophthalmol 2008; 126:1390-1395.
37. Goodin DS, Cohen BA, O'Connor P, et al. Assessment: the use of natalizu-mab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and TechnologyAssessment Subcommittee of the American Academy of Neurology. Neurology 2008; 71:766-773.
38. Cassoux N, Goichot-Bonnat L, Karmochkine M, et al. Efficacy of intravenous immunoglobulin in the treatment of birdshot retinochoroiditis. J Fr Ophtalmol 2002; 25:23-30.
39. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective mono-centric study of 45 patients. Br J Ophthalmol 2007; 91:335-339.
40. Tempest-Roe S, Joshi L, Dick AD, Taylor SR. Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmol 2013; 13:39.
41. Sallam A, Taylor SR, Habot-Wilner Z, et al. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol 2012; 90:e323-e325.
42. Tomkins-Netzer O, Taylor SR, Bar A, et al. Treatment with repeat dexametha-sone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology 2014; 121:1649-1654.
43. Taylor SR, Tomkins-Netzer O, Joshi L, et al. Dexamethasone implant in pediatric uveitis. Ophthalmology 2012; 119:2412-2412.e2.
44. Mruthyunjaya P, Khalatbari D, Yang P, et al. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch Ophthalmol 2006; 124:1012-1018.
45. Burkholder BM, Wang J, Dunn JP, et al. Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot choriore-tinitis and other types of posterior and panuveitis. Retina 2013; 33:1684-1693.
46. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113:1020-1027.
47. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008; 5:1039-1046.
48. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman S. Intravitreal methotrexate in uveitis. Ophthalmology 2012; 119:878-879.
49. Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009; 148:303-309.
50. Pulido JS, Pulido JE, Michet CJ, Vile RG. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well designed trial. Retina 2010; 30:1-5.
51. Furrer E, Berdugo M, Stella C, et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci 2009; 50:771-778.
52. Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect 2013; 3:32.